cbdMD: The Wanted Pullback


  • cbdMD reported a strong March quarter with net revenues growing 26%.
  • The pure-play CBD player guided December quarter sales to grow by 35% to reach nearly $16 million.
  • The stock is cheap at below 3x FY22 sales estimates that appear very low with the potential for the ingestible market to finally move forward.
  • Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio. Learn More »
The U.S. cannabidiol (CBD) space was a tough place to invest in the last year or so. cbdMD (YCBD) was a $6 stock back in mid-2019 and investors can now buy the stock sub-$3 despite the general bullish long-term view of the CBD space. My investment thesis is more bullish on the stock as the mass retailers look to move forward with stocking CBD-infused food products with or without FDA approval.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Skillz: Back To Earth